Brompheniramine

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Brompheniramine
   1. Pharmacist Assessment Report
   2. Brompheniramine: Known uses and market status in Canada
   3. Summary
   4. Quick overview
   5. Known uses among the model’s candidates
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Canada Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Brompheniramine: Known uses and market status in Canada

Summary

The TxGNN deep-learning model produced candidates for Brompheniramine, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. The two known uses are recorded as relations in the knowledge graph, and no approval was found for them in this data.

Quick overview

Item	Content
New predicted indications	None (all traceable model candidates are known uses)
Known uses among model candidates	2
Evidence level	Not applicable
Canada Market Status	Marketed (marketed DINs: 1 of 1)
Number of DINs	1 (marketed: 1)

Known uses among the model’s candidates

Approved (supported by a licence or label)

Indication	Source
none	none

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
allergic urticaria
cold urticaria

Canada Market Information

Licence	Product	Dosage form	Status
02394707	ROBITUSSIN CHILDREN’S COUGH & COLD BEDTIME		Valid

Safety Considerations

Contraindications from the knowledge graph (not label text): The TxGNN knowledge graph links brompheniramine to contraindications or cautions in the following conditions:

• Cardiovascular: hypertension and hypertensive disorder, hypotensive disorder, coronary artery disease, myocardial infarction, coronary thrombosis
• Hepatic, renal and gastrointestinal: liver failure, liver disease, kidney disease, pyoureter, pancreatitis, gallbladder disease, gastric ulcer, peptic ulcer disease, inflammatory bowel disease, Clostridium difficile colitis, perinatal necrotizing enterocolitis
• Respiratory and neurological: epilepsy, chronic obstructive pulmonary disease (including severe early-onset COPD)
• Endocrine and metabolic: hypothyroidism, myxedema, congenital hypothyroidism, diabetes mellitus, diabetic ketoacidosis
• Other: benign prostatic hyperplasia, ocular hypertension, hemoglobinopathy, substance abuse/dependence

Drug interactions: 100 interactions were identified. The main ones are:

• Major: potassium chloride and potassium citrate
• Moderate (anticholinergic agents, additive effects): hyoscyamine, atropine, scopolamine, dicyclomine, clidinium, glycopyrronium, mepenzolate, methscopolamine, propantheline
• Moderate (CNS or opioid agents, additive sedation): morphine (including liposomal), opium, loperamide, eluxadoline, dronabinol, nabilone
• Moderate (other): metoclopramide

Label warnings and contraindications from the Health Canada package insert were not available. Please refer to the package insert for authoritative safety information.

---

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---